PIK3CA and neoplasm: Elucidation of this metabolic regulatory network provides theoretical foundation for combination therapies targeting PI3K–AKT–mTOR pathway inhibitors, with preclinical studies confirming their ability to significantly sensitize tumor cells to FINs.